title: Topically administered macromolecular heparin proteoglycans inhibit thrombus growth in microvascular anastomoses.
abstract: Previously, during blood perfusion over collagen-coated surfaces; soluble or immobilized heparin proteoglycans (HEP-PG) have been shown to block thrombus growth. Our aim was to study the antithrombotic effect of locally applied unfractionated heparin (UFH, 1 mg/ml), or rat mast cell-derived HEP-PG (MW 750 kD, 10 microg/ml) compared with saline in early (10 min) and late (3 days) thrombus formation upon anastomosis of rat common femoral arteries. In both semiquantitative scanning electron microscopy (SEM) and quantitative platelet Indium 111-labeling HEP-PG inhibited thrombus growth in comparison with saline. At 10 min, the extent of thrombosis (scale 1-4) in SEM followed the order: saline (3.2+/-0.8) > UFH (2.8+/-1.0) > HEP-PG (1.8+/-0.8), and also Indium 111-positive platelets (10(6)) accumulated on the anastomosed vessel in the same order 14.2 +/-7.2, 10.3 +/-5.0, and 7.7 +/-3.1 (saline vs. HEP-PG, p = 0.03 and 0.05, respectively). At 3 days all HEP-PG-treated vessels remained patent with only small mural thrombi, whereas 2/7 saline- and 1/7 UFH-treated anastomoses occluded and showed more thrombosis overall. We conclude that locally administered HEP-PG inhibit arterial thrombus growth in anastomosed small-sized arteries and could prevent thrombotic complications in (micro)vascular surgery and arteriovenous shunts.
authors.affiliation: Department of Plastic Surgery, Helsinki University Central Hospital, Finland.
authors.forename: Eija
authors.initials: E
authors.lastname: Olsson
authors.forename: Sirpa
authors.initials: S
authors.lastname: Asko-Seljavaara
authors.forename: Riitta
authors.initials: R
authors.lastname: Lassila
mesh_terms: D000287:Administration, Topical; D000714:Anastomosis, Surgical; D000818:Animals; D001780:Blood Coagulation Tests; D005263:Femoral Artery / Q000601:surgery / Q000648:ultrastructure; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006493:Heparin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D007205:Indium Radioisotopes / Q000032:analysis; D008297:Male; D008855:Microscopy, Electron, Scanning; D023421:Models, Animal; D010973:Platelet Adhesiveness / Q000187:drug effects; D011509:Proteoglycans / Q000008:administration & dosage / Q000627:therapeutic use*; D051381:Rats; D011914:Rats, Inbred BN; D011919:Rats, Inbred Strains; D013927:Thrombosis / Q000517:prevention & control*; D014654:Vascular Patency / Q000187:drug effects
chemical_list: D005343:Fibrinolytic Agents; D007205:Indium Radioisotopes; D011509:Proteoglycans; C036090:heparin proteoglycan; D006493:Heparin